← Human Trials & Peer-Reviewed Studies
The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients.
Plain-language guide to PMID 7955441 (1994): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 7955441
- Journal
- Clinical endocrinology
- Year
- 1994
- Study type
- Randomized Controlled Trial
- Authors
- Russell-Jones DL et al. (7 authors)
- DOI
- 10.1111/j.1365-2265.1994.tb02555.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
Adult patients with growth hormone deficiency are thought to be at higher risk of mortality from cardiovascular disease.
The researchers therefore investigated the effect of recombinant human growth hormone (rhGH) replacement therapy on fasting serum concentrations of lipids, lipoproteins and cholesterol precursors in adult growth hormone deficient patients.
Who Took Part
PubMed indexes the participants as adults and middle-aged adults, both men and women.
Eighteen patients with severe growth hormone deficiency.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
What Was Measured
The subject headings attached to it are Apolipoproteins, Cholesterol, Growth Disorders, Growth Hormone, Lipids, Lipoproteins and Mevalonic Acid.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1994 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.